February 7, 2022
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development…
February 7, 2022
Opportunity: Entrepreneur-In-Residence Role with BioHealth Innovation, Inc. and NIH (2)
POSITION DESCRIPTION – Entrepreneur-In-Residence EIRs will work in collaboration with SEED to mentor innovators and…
February 1, 2022
BHI’s next EIR Feedback Day is February 16th
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in…
February 1, 2022
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence…
February 1, 2022
BioHealth Innovation Announces Updates to its Board of Directors
Board of Directors Elects New Chair, Vice-Chair, and Two New Members ROCKVILLE, MARYLAND, January 31,…